- Article
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience
- Silvia Giordano,
- Paolo Dapavo,
- Michela Ortoncelli,
- Elena Stroppiana,
- Anna Verrone,
- Pietro Quaglino,
- Simone Ribero and
- Luca Mastorino
Background: Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of...